Canada Drug Agency

OAKVILLE, Ontario, June 9, 2026 UCB Canada announced that BIMZELX® (bimekizumab injection) received a positive reimbursement recommendation with conditions...

OTTAWA, Canada, February 2026 — Canada’s Drug Agency (CDA-AMC) has issued a conditional reimbursement recommendation for Opdivo® (nivolumab) plus...

Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...